Medicines Marketed by Astrazeneca Pharma India Ltd

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd, established in 1979, is a leading pharmaceutical company operating in the healthcare sector. Headquartered in Bengaluru, Karnataka, the company is a subsidiary of AstraZeneca Plc, UK, which allows it to leverage global resources and expertise while maintaining a strong presence in India. With a dedicated workforce of over 900 employees, Astrazeneca Pharma India Ltd is committed to delivering life-changing medicines across the country and beyond.

The company's diverse portfolio includes innovative medicines in crucial areas of healthcare, such as cardiovascular diseases, renal and metabolic disorders, oncology, and respiratory conditions. Astrazeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of a wide range of pharmaceutical products, ensuring that patients have access to high-quality treatments for their health needs.

Astrazeneca Pharma India Ltd Products

Astrazeneca Pharma India Ltd is renowned for its extensive range of therapeutic products, with a focus on cardiovascular health, oncology, respiratory care, and recent launches. The company's cardiovascular products target hypertension and heart failure, while its oncology division offers innovative cancer treatments. In the respiratory segment, Astrazeneca Pharma India Ltd provides medicines for asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is also set to launch Palivizumab in October 2024, a monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in high-risk infants.

Astrazeneca Pharma India Ltd stands out in the market for its commitment to innovative science, global excellence, and dedication to patient safety. The company leverages international expertise and resources from the global AstraZeneca network, ensuring high standards in the development and commercialisation of its medicines. With a strong financial profile, including a market capitalisation of approximately ?19,343 crore and robust financial ratios, Astrazeneca Pharma India Ltd is well-positioned for stability and growth in the Indian pharmaceutical sector.